Advocates, patients press Joint Committee to require insurer coverage for biomarker testing

Summary

Patients, clinicians and advocacy groups told the Joint Committee on Financial Services that biomarker tests — genomic and protein assays that guide targeted cancer and Alzheimer’s treatments — must be covered routinely by insurers to speed correct treatment, reduce costs and close equity gaps.

Lawmakers heard hours of testimony Tuesday urging the Joint Committee on Financial Services to require private insurers to cover biomarker testing when medically appropriate, citing patient stories and clinical outcomes.

Speakers told the committee that biomarker tests — including genomic panels, liquid biopsies and amyloid assays — can identify targeted therapies for cancer and disease‑modifying treatment for Alzheimer’s disease, but that patchwork coverage and denials delay care or leave patients to pay thousands out of pocket.

Supporters said broader coverage would improve outcomes and reduce long‑term costs. ‘‘Timely access to guideline‑indicated comprehensive biomarker testing will enable more patients to access the most effective treatments for their disease and can potentially help with…

Advocates, patients press Joint Committee to require insurer coverage for biomarker testing

Summary

Subscribe to keep reading